Call to Schedule Free Consultation at Over 80 Centers Worldwide!

(844) GET-STEM

New Tennessee Stem Cell Law HB 2246: What It Means for Patients

Written by Dr. David Greene, MD, PhD, MBA on May 6, 2026

Table of Contents

Tennessee just took a meaningful step toward clearer, more accountable regenerative medicine. In April 2026, the state passed House Bill 2246, which establishes a statewide framework for regenerative stem cell therapy. For Nashville-area patients who have spent the last several years sorting through conflicting claims about regenerative medicine, this is one of the more significant policy shifts in recent memory — and it’s worth understanding what the law actually does, what it does not do, and how to evaluate a provider in the new environment.

What HB 2246 actually does

HB 2246 sets statewide standards for how regenerative stem cell therapy can be offered in Tennessee. In broad terms, the law:

Authorizes qualified physicians to offer both autologous (from the patient’s own body) and allogeneic (donor-sourced) stem cell therapies.

Requires that cells used in these therapies come from FDA-registered or accredited tissue establishments.

Establishes baseline expectations around physician qualifications, informed consent, and patient safety.

Creates a clearer regulatory pathway for the practice of regenerative medicine inside the state.

The framing here matters. The law is not a green light to do anything in the name of regenerative medicine — it is a structure that defines how reputable providers should operate, what cell sources are acceptable, and what patients should be told before they make a decision.

What HB 2246 does not change

Federal law still applies. The U.S. Food and Drug Administration continues to regulate human cells, tissues, and cellular and tissue-based products under 21 CFR Part 1271 and the Public Health Service Act. State law cannot override federal authority.

It does not approve any product as a treatment for any specific disease. Stem cell products described under the new framework are not FDA-approved as treatments for conditions such as arthritis, autoimmune disease, neurological disease, or any other indication.

It does not guarantee outcomes. Regenerative medicine remains an evolving field. Individual responses vary, and any provider promising specific results should be approached with skepticism.

A more accurate way to think about HB 2246 is that Tennessee has clarified the rules of the road. It has not remade the destination.

Autologous vs. allogeneic: a quick primer

One of the most common questions Nashville patients ask is what kind of cells are actually used. Under HB 2246, both categories are recognized:

Autologous stem cells are harvested from the patient’s own body — most commonly bone marrow or adipose (fat) tissue. The advantage is biological compatibility; the cells are the patient’s own. The trade-off is that a harvest procedure is required, and the cells reflect the patient’s age and health.

Allogeneic stem cells are sourced from screened donors, typically from umbilical cord or placental tissue collected after healthy live births. They are processed at FDA-registered facilities. The advantage is availability and consistency; the trade-off is that they come from a donor rather than the patient.

Neither category is universally “better.” Which approach a physician recommends — if any — depends on the patient, the situation, and what the evidence supports for that situation.

What Nashville patients should look for in a provider

If you are considering a consultation in the new HB 2246 environment, here are five questions worth asking any clinic before you book:

Who is performing the procedure? Look for certified physicians with documented training in interventional or regenerative medicine.

Where do the cells come from? Reputable providers source from FDA-registered or accredited tissue establishments and will tell you the source on request.

What does the consultation actually cover? A genuine evaluation should review your medical history, current imaging, prior treatments, and a frank discussion of whether regenerative medicine is even appropriate for your situation. Anyone selling you a treatment before evaluating you is not evaluating you.

What is the informed consent process? You should receive clear, written information about the procedure, the cell product, what is known and unknown about outcomes, and the costs involved.

What does follow-up look like? Reputable practices schedule structured follow-up visits and track patient progress over time, not only at the moment of payment.

These questions are the same whether you visit our practice or another. The point is that HB 2246 gives Tennessee patients a stronger basis for asking them.

R3 Stem Cell Nashville under the new framework

R3 Stem Cell Nashville operates as a Nashville-area regenerative medicine practice within the framework established by HB 2246. Patients meet with credentialed physicians, review their history and goals, and receive an honest evaluation of whether a regenerative medicine consultation is appropriate for their situation. Cells used in any procedure are sourced from FDA-registered tissue establishments. Informed consent and patient education come before any decision about next steps.

If you have been researching regenerative options in Tennessee and want a straightforward conversation rather than a sales pitch, R3 Stem Cell Nashville is set up for exactly that kind of consultation.

As the world’s largest regenerative therapy provider with 80 Centers in 8 Countries, R3 has performed 28,000 stem cell procedures in the past decade. With an 85% patient satisfaction rate, there is no Tennessee stem cell clinic that offers the quality, safety standards and affordability combined!

Schedule a consultation

The most important thing HB 2246 changes is the level of clarity Tennessee patients can now expect from any regenerative medicine provider. Use that clarity. Ask the questions above. Bring your records. Take your time.

To schedule a consultation at R3 Stem Cell Nashville, visit r3stemcell.com/nashville-tn or call the Nashville office directly at (615) 835-2690. Consultations are evaluative, not commitments to treatment.

Important information

This article is for general informational and educational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. Stem cell products described in this article are not FDA-approved as treatments for any specific disease or condition. Tennessee HB 2246 establishes a state-level regulatory framework and does not modify federal law or the authority of the U.S. Food and Drug Administration. Individual results vary, and a consultation is not a guarantee of any particular outcome. Patients should review all options with a qualified physician and rely on their own informed judgment when making medical decisions.

Contact Us